Qube Research & Technologies (QRT)’s Xenon Pharmaceuticals XENE Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-44,044	Closed	-$2.56M	–	4172
2026 Q1	$2.56M	Buy	+44,044	New	+$2.03M	﹤0.01%	2026
2024 Q4	–	Sell	-6,938	Closed	-$273K	–	3867
2024 Q3	$273K	Sell	6,938 -40,904	-85%	-$1.65M	﹤0.01%	2462
2024 Q2	$1.87M	Buy	47,842 +2,556	+6%	+$102K	﹤0.01%	1662
2024 Q1	$1.95M	Buy	+45,286	New	+$2.08M	﹤0.01%	1778
2023 Q4	–	Sell	-54,285	Closed	-$1.85M	–	4803
2023 Q3	$1.85M	Buy	54,285 +24,318	+81%	+$910K	﹤0.01%	1425
2023 Q2	$1.15M	Buy	29,967 +15,514	+107%	+$617K	﹤0.01%	1245
2023 Q1	$517K	Sell	14,453 -61,306	-81%	-$2.26M	﹤0.01%	1558
2022 Q4	$2.99M	Buy	75,759 +41,276	+120%	+$1.5M	0.02%	807
2022 Q3	$1.25M	Buy	+34,483	New	+$1.24M	0.01%	1116
2022 Q1	–	Sell	-14,304	Closed	-$447K	–	3088
2021 Q4	$447K	Buy	+14,304	New	+$427K	﹤0.01%	1624

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Qube Research & Technologies (QRT)'s XENE Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Xenon Pharmaceuticals (XENE) in Q2 2026, closing a stake of 44,044 shares — an estimated $2.56M sold.

Qube Research & Technologies (QRT) first reported a position in XENE in Q4 2021 and held it in 10 quarters. The position peaked at $2.99M in Q4 2022. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Qube Research & Technologies (QRT) reported no remaining Xenon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Qube Research & Technologies (QRT) sold 44,044 Xenon Pharmaceuticals shares in Q2 2026, an estimated $2.56M.
Qube Research & Technologies (QRT) first reported a position in Xenon Pharmaceuticals in Q4 2021 and held it in 10 quarters.
Qube Research & Technologies (QRT)'s Xenon Pharmaceuticals position peaked at $2.99M in Q4 2022.
316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.